SRPT Ian Michael Estepan sells $294K worth of shares
Dec 19, 2025, 5:35 AM
0.00%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
Ian Michael Estepan sold 13,187 shares of SRPT on 16 December at $22.31 per share, worth a total of $294K. They now own 193,300 SRPT shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.